Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

Revolutionizing CGM Accessibility and Performance Trinity Biotech’s redesigned ergonomic modular CGM system is designed with affordability, accuracy, and sustainability in mind. The device’s ...

(MENAFN- GlobeNewsWire - Nasdaq) Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Feb. 06, 2025 (GLOBE ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech ...

Trinity Biotech's next-generation CGM system includes reusable and rechargeable components, aiming to make the technology more affordable and environmentally friendly. This development could ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...